Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

NDA submissions for bezuclastinib in Gastrointestinal Stromal Tumors (GIST) and Advanced Systemic Mastocytosis (AdvSM) are on-track for the first half of 2026 based on the strength of clinical results ...

Stage 1 myelofibrosis is a chronic condition with minimal symptoms, requiring early diagnosis for effective monitoring and intervention. Treatment options include active surveillance, JAK inhibitors, ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Inflammatory molecules circulating in the blood may worsen disease symptoms and points to new opportunities for targeted therapy.

Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...

Company to present at 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15Label expansion submissions for BESREMi® (ropeginterferon alfa-2b-njft) filed with FDABURLINGTON, ...

Research links variations in the gene GRIN2A to a higher risk of developing schizophrenia and other forms of mental illness. The GRIN2A gene regulates communication between neurons by producing the ...

In a breakthrough study, scientists have discovered that a variant in one gene, GRIN2A, can directly cause mental illness – something previously believed to be the result of several mutations working ...